Wilmington Savings Fund Society FSB Invests $93,000 in Hologic, Inc. (NASDAQ:HOLX)

Wilmington Savings Fund Society FSB acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 1,137 shares of the medical equipment provider’s stock, valued at approximately $93,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in HOLX. Wolff Wiese Magana LLC bought a new position in Hologic during the 3rd quarter valued at $25,000. Innealta Capital LLC acquired a new stake in shares of Hologic in the second quarter valued at $25,000. First Horizon Advisors Inc. boosted its stake in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares in the last quarter. Sunbelt Securities Inc. acquired a new position in Hologic during the second quarter worth about $37,000. Finally, Cromwell Holdings LLC grew its holdings in Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 416 shares during the period. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the subject of several research reports. Evercore ISI raised their price objective on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Jefferies Financial Group initiated coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price for the company. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and dropped their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Wolfe Research initiated coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Finally, BNP Paribas upgraded Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Six analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $89.50.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.75% of the company’s stock.

Hologic Stock Up 1.3 %

NASDAQ:HOLX opened at $71.65 on Friday. Hologic, Inc. has a 1-year low of $70.36 and a 1-year high of $84.67. The firm has a market capitalization of $16.26 billion, a price-to-earnings ratio of 21.52, a PEG ratio of 2.38 and a beta of 0.96. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The business’s fifty day moving average price is $78.65 and its 200 day moving average price is $78.52.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 EPS. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.